Table 2. Summary of the microbiological studies of the clinical isolates of Candida auris in Korea
Year of publication No. of patient (No. of isolate) Specimen (No. of isolate) Molecular epidemiologic test (No. of isolate)a Resistance rate of antifungal agent (%)b Possible genetic marker of FLU resistant isolate Reference
FLU AMB CSF MCF ANF
2009 15 (15) Ear (15) NT 53.3 0 0 0 NT NT [46]
2011 3 (6) Blood (6) NT 33.3 0 0 0 NT NT [44]
2018 61 (61) Blood (4), Ear (57) Clade II (61) 62.3 0 0 0 NT Erg11p (L43H, K143R, Q357K) [52]
2023 104 (104) Blood (5), Ear (91) Clade I (8) 25.0 75.0 0 0 0 Erg11p (K143R), Tac1Bp (A640V) [20]
Clade II (96) 68.8 0 0 0 0 Erg11p (L43H, Y132F, K143R, Q357K), Tac1Bp (F214S, P595L)

aClade of isolates were determined by multilocus sequence typing.
bApplying tentative breakpoints of the Centers for Disease Control and Prevention.
Abbreviations: FLU, fluconazole; AMB, amphotericin B; CSF, Caspofungin; MCF, micafungin; ANF, anidulafungin; NT, not tested.